Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04157322 · ClinicalTrials.gov registry record
Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis
A clinical trial of Colorectal Cancer Metastatic and Appendix Cancer, sponsored by University of Chicago.
- Active
- Registry status
- 55
- Enrollment target
- 1
- Study location
NCT04157322: Active study of Colorectal Cancer Metastatic and Appendix Cancer, sponsored by University of Chicago.
NCT04157322 is a study of Colorectal Cancer Metastatic and Appendix Cancer that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 55 participants, below the 202-participant average among 18 other Colorectal Cancer Metastatic trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04157322, a study of Colorectal Cancer Metastatic and Appendix Cancer, is active but no longer recruiting, sponsored by University of Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with peritoneal metastasis of colorectal or high grade appendiceal origin who are candidates for cytoreductive surgery with HIPEC (hyperthermic intraperitoneal chemotherapy) will be enrolled in this study. Blood collection for measurements of plasma cell-free DNA hydroxymethylation signatures will be performed at different time points, before and after surgery, in order to determine if plasma hydroxymethylation signatures are more sensitive than conventional tumor markers in identifying clinically detectable recurrence at 1 year after surgery.
Primary Outcome
1. Clear radiological evidence of recurrent disease. 2. Histopathological proof (by means of endoscopy, imaging guided biopsy or diagnostic surgery) of recurrent disease. 3. A new lesion revealed by physical examination
Conditions Studied
Interventions
- DIAGNOSTIC_TEST prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study
Study Locations (1)
Illinois
- The University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2027-10-31 |
What the registry record for NCT04157322 still lists
NCT04157322 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 202-participant average among 18 other Colorectal Cancer Metastatic trials with a reported enrollment target (73% lower).
The record links to 4 conditions, with Colorectal Cancer Metastatic appearing as the primary indexed condition, and to 1 intervention - of which prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study is the first listed.
NCT04157322 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT04157322 about?
NCT04157322 is a clinical study titled "Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis". Patients with peritoneal metastasis of colorectal or high grade appendiceal origin who are candidates for cytoreductive surgery with HIPEC (hyperthermic intraperitoneal chemotherapy) will be enrolled in this study. Blood collection for measurements of plasma cell-free DNA hydroxymethylation signatur...
What is the current status of trial NCT04157322?
This trial is currently active not recruiting. The enrollment target is 55 participants. The study started on 2019-08-26. Estimated completion is 2027-10-31.
What conditions does trial NCT04157322 study?
This clinical trial studies the following conditions: Colorectal Cancer Metastatic, Appendix Cancer, Colorectal Cancer Stage IV, Colorectal Cancer, Genetics of.
What interventions are being tested in trial NCT04157322?
The interventions under investigation include: prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04157322?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04157322 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04157322's enrollment target sits among peer trials
55 9th of 18 higher than 10 of 18 other Colorectal Cancer Metastatic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer Metastatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
RECRUITING · Phase 2
-
Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases
RECRUITING
-
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
RECRUITING · Early Phase 1
-
Colorectal Metastasis to Liver Extraction With Auxiliary Transplant and Delayed Resection
RECRUITING
-
INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases
RECRUITING · Early Phase 1
-
Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI